dermaPACE® vs. NPWT vs. Cellular Matrix

¹ Wang C-J, et al. Treatment of diabetic foot ulcers: A comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy. Diab Res Clin Pract (2011), doi:10.1016/j.diabres.2011.01.019

²Limited strictly to the wound bed due to limitations of the sponge/pad and VAC Device.

³Tanaka T, et. al. Negative pressure wound therapy induces early wound healing by increased and accelerated expression of vascular endothelial growth factors. Eur J Plast Surg (2016) 39:247-256. Limited to VEGF.

⁴Various chenokine, cytokino, and growth factors are intrinsic to grafts/applications and are introduced into the wound bed. However, these products don't appear to stimulate additional growth factor generation.

⁵dermaPACE® FDA Clinical Support and Device Description, January 2018. FDA de novo clearance as Class II device on December 28, 2017.

⁶Blume PA, et. al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diab Care (2008), Apr; 31(4):631-6. Epub 2007 Dec 27.

⁷Frykberg RG, Williams DV. Negative pressure wound therapy and diabetic foot amputations: a retrospective study of payer claims data. J Am Podiatr Med Assoc. 2007 Sep-Oct;97(5):351-9

⁸Apligraf FDA Summary of Safety & Effectiveness Data, June 20, 2000, as proxy for cellular matrix.

⁹GSA Scheduled total cost of equipment rental, use, consumables and labor @ $30/hr. dermaPACE® labor component is insignificant and not noted.

¹⁰Weekly Cost divided by 7.

¹¹Average Daily Cost times Time-to-closure, above.